Bailard
NVS icon

Bailard’s Novartis NVS Stock Holding History

Bailard’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.16M Buy
15,119
+1,250
+9% +$190K 0.04% 244
2026
Q2 		$2.17M Buy
13,869
+587
+4% +$88K 0.04% 250
2026
Q1 		$2.03M Sell
13,282
-1,144
-8% -$175K 0.05% 231
2025
Q4 		$1.99M Buy
14,426
+2,305
+19% +$302K 0.04% 229
2025
Q3 		$1.55M Buy
12,121
+1,418
+13% +$173K 0.03% 272
2025
Q2 		$1.3M Buy
10,703
+580
+6% +$65.4K 0.03% 291
2025
Q1 		$1.13M Buy
10,123
+4,160
+70% +$443K 0.03% 290
2024
Q4 		$580K Buy
5,963
+283
+5% +$30.2K 0.01% 431
2024
Q3 		$653K Buy
5,680
+1,593
+39% +$181K 0.02% 414
2024
Q2 		$435K Buy
4,087
+661
+19% +$66.4K 0.01% 479
2024
Q1 		$331K Buy
+3,426
New +$351K 0.01% 542
2021
Q1 		– Sell
-9,088
Closed -$858K – 727
2020
Q4 		$858K Buy
9,088
+550
+6% +$48.1K 0.04% 236
2020
Q3 		$742K Buy
8,538
+485
+6% +$42K 0.04% 234
2020
Q2 		$703K Buy
8,053
+3,102
+63% +$268K 0.04% 225
2020
Q1 		$408K Sell
4,951
-956
-16% -$85.3K 0.03% 258
2019
Q4 		$559K Sell
5,907
-33
-0.6% -$2.96K 0.03% 257
2019
Q3 		$516K Buy
5,940
+600
+11% +$53.9K 0.03% 263
2019
Q2 		$487K Buy
5,340
+172
+3% +$14.6K 0.03% 290
2019
Q1 		$446K Buy
+5,168
New +$415K 0.03% 324

Other funds holding NVS

Ferguson Wellman Capital Management
Ferguson Wellman Capital Management Portland, Oregon $8.38B AUM 25.07% 1-Year Est. Return
Godsey & Gibb Inc
Godsey & Gibb Inc Richmond, Virginia $1.21B AUM 18.94% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
TD Waterhouse Canada
TD Waterhouse Canada Toronto, Ontario, Canada $38.4B AUM 30.28% 1-Year Est. Return
Matthew Goff Investment Advisor
Matthew Goff Investment Advisor Houston, Texas $672M AUM 21.65% 1-Year Est. Return
ERP
Eldred Rock Partners San Antonio, Texas $451M AUM 38.39% 1-Year Est. Return
Salem Investment Counselors
Salem Investment Counselors Winston Salem, North Carolina $4.01B AUM 48.23% 1-Year Est. Return
Mengis Capital Management
Mengis Capital Management Portland, Oregon $673M AUM 34.75% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Bailard's NVS Position: Q3 2026 in Review

Bailard increased its Novartis (NVS) stake by 9% in Q3 2026, buying an estimated $190K and bringing the position to 15,119 shares worth $2.16M. The position accounts for 0.04% of the portfolio, ranked #244.

Bailard first reported a position in NVS in Q1 2019 and has held it in 19 quarters since. The position peaked at $2.17M in Q2 2026. 310 funds tracked by Wall St. Rank hold NVS as of Q3 2026.

  • Bailard held 15,119 shares of Novartis worth $2.16M as of Q3 2026.
  • Bailard bought 1,250 Novartis shares in Q3 2026, an estimated $190K.
  • Novartis made up 0.04% of Bailard's portfolio in Q3 2026, its #244 holding.
  • Bailard first reported a position in Novartis in Q1 2019 and has held it in 19 quarters since.
  • Bailard's Novartis position peaked at $2.17M in Q2 2026.
  • 310 funds tracked by Wall St. Rank held Novartis as of Q3 2026.

Based on Bailard's 13F filing for Q3 2026, filed 13 Oct 2026.